Merck Sharp & Dohme LLC has identified compounds acting as NLRP3 inflammasome inhibitors reported to be useful for the treatment of atherosclerosis, nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH), neuroinflammation, inflammatory skin, inflammatory joint and autoimmune diseases, Alzheimer’s disease and Parkinson’s disease, among others.

Frontier Medicines Corp. has synthesized GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer.

Acrivon Therapeutics Inc. has disclosed membrane-associated tyrosine- and threonine-specific Cdc2-inhibitory kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.

The bill the U.S. Senate passed to prune biologic patent thickets could be among the first in a legislative thicket aimed at prescription drug prices to make it through the Senate before the year ends.

RTI International has described cannabinoid CB1 receptor antagonists reported to be useful for the treatment of metabolic syndrome, binge-eating disorder, Prader-Willi syndrome, alcoholism, nicotine dependence and cannabis abuse.

Gossamer Bio Inc. has divulged diacylglycerol kinase α (DGK-α) and/or diacylglycerol kinase ζ (DGK-ζ) inhibitors reported to be useful for the treatment of cancer and viral infections.

LG Chem Ltd. has identified macrophage stimulating 1 receptor (MST1R; RON) inhibitors reported to be useful for the treatment of cancer and immunological disorders.

Chengdu Easton Biopharmaceuticals Co. Ltd. has synthesized oxalamide derivatives acting as protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.

Xinthera Inc. has disclosed integrin α4β7 (LPAM-1) antagonists reported to be useful for the treatment of inflammatory bowel disease, colitis, pouchitis, gastroenteritis, eosinophilic esophagitis and lung inflammatory disease.